Page last updated: 2024-11-08

gitoxigenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gitoxigenin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID608933
SCHEMBL ID19638184
MeSH IDM0051269
PubMed CID348482
CHEMBL ID464658
CHEBI ID38105
SCHEMBL ID644087
MeSH IDM0051269

Synonyms (73)

Synonym
smr001565323
3-(3,14,16-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl)-2h-furan-5-one
nsc 407807
3,14,16-trihydroxycard-20(22)-enolide
16.beta.-hydroxydisitoxigenin
mls002701727 ,
AKOS015998298
FT-0626709
cid_608933
bdbm96075
3-[10,13-dimethyl-3,14,16-tris(oxidanyl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2h-furan-5-one
5.beta.-card-20(22)-enolide, 3.beta.,14,16.beta.-trihydroxy-
card-20(22)-enolide, 3,14,16-trihydroxy-, (3.beta.,5.beta.,16.beta.)-
3,14,16-trihydroxycard-20(22)-enolide, (3.beta.)-
PVAMXWLZJKTXFW-UHFFFAOYSA-N
3-.beta.,14,16-trioxycarden-(20:22)-olid
cardogenen-(20:22)-triol-(3.beta.,14,16)
bigitaligenin
.delta.(20,22)-2,14,16,21-(tetrahydroxy)norcholenic acid lactone
3-.beta.,14,16-trioxy-digen-(20:22)-olid
SCHEMBL19638184
STL560747
DTXSID00871752
5-18-04-00385 (beilstein handbook reference)
3-beta,14,16-trioxy-digen-(20:22)-olid
3-beta,14,16-trioxycarden-(20:22)-olid
unii-g36k2h8sme
cardogenen-(20:22)-triol-(3-beta,14,16)
g36k2h8sme ,
NCI60_003893
MEGXP0_001900
cardogenen-(20:22)-triol-(3-beta,14,16) [german]
5-beta-card-20(22)-enolide, 3-beta,14,16-beta-trihydroxy-
delta(20,22)-2,14,16,21-tetrahydroxynorcholenic acid lactone
5beta-card-20(22)-enolide, 3beta,14,16beta-trihydroxy-
3-beta,14,16-beta-trihydroxy-5-beta,14-beta-card-20(22)-enolide
card-20(22)-enolide, 3,14,16-trihydroxy-, (3-beta,5-beta,16-beta)-
brn 0096483
16beta-hydroxydisitoxigenin
16-beta-hydroxydigitoxigenin
3-beta,14,16-trioxy-digen-(20:22)-olid [german]
card-20(22)-enolide, 3,14,16-trihydroxy-, (3beta,5beta,16beta)-
3-beta,14,16-trioxycarden-(20:22)-olid [german]
einecs 208-886-2
3beta,14,16beta-trihydroxy-5beta-card-20(22)-enolide
16beta-hydroxydigitoxigenin
CHEBI:38105 ,
16.beta.-hydroxydigitoxigenin
.delta.(20,14,16,21-(tetrahydroxy)norcholenic acid lactone
card-20(22)-enolide,14,16-trihydroxy-, (3.beta.,5.beta.,16.beta.)-
gitoxigenin
nsc-407807
545-26-6
5.beta.-card-20(22)-enolide,14,16.beta.-trihydroxy-
NSC407807 ,
.delta.20,14,16,21-(tetrahydroxy)norcholenic acid lactone
CHEMBL464658
LMST01120003
3-[(3s,5r,8r,9s,10s,13r,14s,16s,17r)-3,14,16-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2h-furan-5-one
gitoxigenin [mi]
CCG-208473
SCHEMBL644087
AKOS030490030
SR-05000002231-2
sr-05000002231
SR-05000002231-3
bdbm225705
cs334
PVAMXWLZJKTXFW-VQMOFDJESA-N
Q1527718
DTXSID20878642
CS-0185737
HY-W127509

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Selected cardiac glycosides were tested in combination with four clinically relevant cytotoxic drugs (5-fluorouracil, oxaliplatin, cisplatin, irinotecan)."( Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
Bohlin, L; Felth, J; Fryknäs, M; Gullbo, J; Lindskog, M; Rickardson, L; Rosén, J; Wickström, M, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
3beta-hydroxy steroidA 3-hydroxy steroid in which the 3-hydroxy substituent is in the beta-position.
14beta-hydroxy steroidA 14-hydroxy steroid in which the hydroxy group has a beta-configuration.
16beta-hydroxy steroidA 16-hydroxy steroid in which the hydroxy group at position 16 has a beta-configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency5.01190.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency9.08440.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency10.00000.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency1.51860.00018.4406100.0000AID720579; AID720580
IDH1Homo sapiens (human)Potency4.61090.005210.865235.4813AID686970
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency79.43280.354828.065989.1251AID504847
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency1.83560.00419.984825.9290AID504444
gemininHomo sapiens (human)Potency12.58450.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID1745849Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745847CMV-Luciferase Counterscreen for Inhibitors of ATXN expression
AID1745846Firefly Luciferase Counterscreen for Inhibitors of ATXN expression
AID1745850Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression
AID1745848Confirmatory qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID471508Cytotoxicity against human CC20 cells assessed as survival index at 10 uM after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID146869In vitro inhibition of hog kidney Na+, K+, ATPase.1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Cardiac glycosides. 6. Gitoxigenin C16 acetates, formates, methoxycarbonates, and digitoxosides. Synthesis and Na+,K+-ATPase inhibitory activities.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID127350Binding affinity against human monoclonal antibody (mAb)-1B32002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127352Binding affinity against human monoclonal antibody (mAb)-7F22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127479Binding affinity against murine monoclonal antibody (mAb)-40-502002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID399011Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID399010Cytotoxicity against human TK10 cells after 48 hrs by SRB assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID399012Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
AID127349Binding affinity against human monoclonal antibody (mAb)-11E62002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID357577Binding affinity to mouse Monoclonal antibody DIG 64.2B.5 by ELISA relative to digoxin
AID471510Cytotoxicity against human HT-29 cells assessed as survival index at 10 uM after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID127351Binding affinity against human monoclonal antibody (mAb)-5C22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID471509Cytotoxicity against human HCT116 cells assessed as survival index at 10 uM after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (37.50)18.7374
1990's0 (0.00)18.2507
2000's5 (20.83)29.6817
2010's8 (33.33)24.3611
2020's2 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.24 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index76.15 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1 (4.76%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
Other20 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]